Adaptive Biotechnologies (ADPT) Non-Current Debt (2022 - 2026)

Adaptive Biotechnologies has reported Non-Current Debt for 5 years, with the latest figure at $124.7 million in Q1 2026.

• Quarterly Non-Current Debt fell 5.17% year-over-year to $124.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.7 million (down 5.17% YoY) and the FY2025 annual result came in at $126.6 million, down 4.42% from the prior year.
• Non-Current Debt declined to $124.7 million in Q1 2026 per ADPT's latest filing, from $126.6 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $132.7 million in Q3 2024 and troughed at $124.7 million in Q1 2026.
• A 5-year average of $129.5 million and a median of $130.6 million in 2023 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2026: Non-Current Debt increased 4.71% in 2024, then slipped 5.17% in 2026.
• Over 5 years, Non-Current Debt stood at $125.4 million in 2022, then increased by 4.23% to $130.7 million in 2023, then advanced by 1.34% to $132.4 million in 2024, then decreased by 4.42% to $126.6 million in 2025, then slipped by 1.44% to $124.7 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $124.7 million, $126.6 million, and $129.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.